Acadia received a higher share target from RBC, which kept its Outperform rating and cited Daybue's continued sales momentum. This favorable analyst view supports ACAD, but reports no new company result.
That gives investors a favorable outside view, backed by analysts' praise for Daybue's continued sales momentum after the third quarter. It is analyst opinion, not a new company result.
Follow Acadia Pharmaceuticals Inc. (ACAD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ACAD